Cardiovascular capabilities available on Toshiba's ultracompact high-field MR system were highlighted at the annual meeting of the American College of Cardiology, March 7 to 10 in New Orleans. Vantage, which was formally released at the 2003 RSNA
Cardiovascular capabilities available on Toshiba's ultracompact high-field MR system were highlighted at the annual meeting of the American College of Cardiology, March 7 to 10 in New Orleans. Vantage, which was formally released at the 2003 RSNA meeting, supports a range of CV studies from stroke evaluation to peripheral vascular imaging. The ultrashort bore provides a feeling of openness; Pianissimo technology reduces scan noise. SuperFASE supports morphology studies of vascular structures, including the heart chambers and large vessels, as well as MR angiograms of venous and arterial vessels. Toshiba's parallel imaging technology, called Speeder, allows high-speed, high-resolution imaging, cutting exam time by as much as a factor of three.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.